We conducted a blind and independent “voice of the customer” industry survey in late Q4 2020 and into early Q1 2021 with the opt-in online readership of Contract Pharma to ascertain what impact COVID-19 had and was continuing to have on outsourcing decisions for those who sought CRO, CDMO, or both CRO and CDMO services in the global pharmaceutical industry.
The insights provided by survey respondents reveal what happened within the outsourcing industry in 2020, where it’s going in 2021, and the role COVID-19 played in dramatically shifting attitudes, preferences and actions within the global pharmaceutical supply chain.
In part four of our series, we gauge and reflect how the impact of COVID-19 is influencing and will influence preferences for CRO/CDMO partners based on their location. Specifically, is there a trend towards US-based providers of CRO/CDMO services? Is there any variance among the different segments: those who are seeking CRO services only; those seeking CDMO services only; and those seeking both CRO/CDMO services?
Discover part one of the series here.
Discover part two of the series here.
Discover part three of the series here.